Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Jazz Pharmaceuticals plc
  6. News
  7. Summary
    JAZZ   IE00B4Q5ZN47

JAZZ PHARMACEUTICALS PLC

(JAZZ)
  Report
Delayed Nasdaq  -  04:00:01 2023-02-03 pm EST
155.64 USD   -0.49%
01/27UBS Adjusts Jazz Pharmaceuticals Price Target to $192 From $191, Maintains Buy Rating
MT
01/26U.S. FDA calls for new regulatory framework for use of cannabis compound CBD
RE
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Carried Higher in Market Rally

11/10/2022 | 03:55pm EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
10X GENOMICS, INC. -3.78% 47.84 Delayed Quote.36.44%
JAZZ PHARMACEUTICALS PLC -0.49% 155.64 Delayed Quote.-1.83%
PRIVIA HEALTH GROUP, INC. -6.28% 25.96 Delayed Quote.21.97%
VERU INC. -2.54% 5.76 Delayed Quote.11.93%
All news about JAZZ PHARMACEUTICALS PLC
01/27UBS Adjusts Jazz Pharmaceuticals Price Target to $192 From $191, Maintains Buy Rating
MT
01/26U.S. FDA calls for new regulatory framework for use of cannabis compound CBD
RE
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phas..
AQ
01/19Jazz Pharmaceuticals, Zymeworks Announce Positive Results From Phase 2 Trial of Esophag..
MT
01/19Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Pha..
CI
01/09Transcript : Jazz Pharmaceuticals plc Presents at 41st Annual J.P. Morgan Hea..
CI
01/09Jazz Pharmaceuticals : JPM 2023 Presentation
PU
01/04Jazz Pharmaceuticals Plc : Other Events (form 8-K)
AQ
01/03Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
PR
01/03Hikma launches version of Xyrem medicine in US for treating narcolepsy
AN
More news
Analyst Recommendations on JAZZ PHARMACEUTICALS PLC
More recommendations
Financials (USD)
Sales 2022 3 665 M - -
Net income 2022 1,05 M - -
Net Debt 2022 4 325 M - -
P/E ratio 2022 -231x
Yield 2022 -
Capitalization 9 848 M 9 848 M -
EV / Sales 2022 3,87x
EV / Sales 2023 3,53x
Nbr of Employees 3 200
Free-Float 97,5%
Chart JAZZ PHARMACEUTICALS PLC
Duration : Period :
Jazz Pharmaceuticals plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAZZ PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 155,64 $
Average target price 200,63 $
Spread / Average Target 28,9%
EPS Revisions
Managers and Directors
Bruce C. Cozadd Chairman & Chief Executive Officer
Daniel N. Swisher President
Renée D. Galá Chief Financial Officer & Executive Vice President
Robert Iannone Chief Medical Officer, EVP-Research & Development
Finbar Larkin Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
JAZZ PHARMACEUTICALS PLC-1.83%9 848
JOHNSON & JOHNSON-6.29%432 802
ELI LILLY AND COMPANY-6.36%314 224
NOVO NORDISK A/S-3.40%300 394
ROCHE HOLDING AG-5.73%264 917
MERCK & CO., INC.-6.75%262 312